and tend to have more consistent serum levels compared with cytokines themselves. [16] [17] [18] [19] To date, independent association of these receptors with risk for HF has not been rigorously evaluated. 20 In this study, we aimed to assess the association of baseline sTNF-R1 and sTNF-R2 levels and incident HF risk in older adults.
Methods

Study Population
The study population included participants in the Health, Aging, and Body Composition (Health ABC) Study, a population-based cohort of 3075 participants who were 70 to 79 years of age at inception and recruited from April 1997 to June 1998 from areas surrounding Pittsburgh, PA, and Memphis, TN. To be eligible, study participants had to (1) report no difficulty in walking a quarter mile, climbing 10 stairs without resting, or performing basic activities of daily living; (2) be free of life-threatening illness; and (3) have no intention of moving within 3 years. Participants had telephone contacts every 6 months and clinical visits every year. Clinical diseases at baseline were ascertained using algorithms similar to the Cardiovascular Health Study. 21 The institutional review boards approved the protocol. These results represent the outcomes during 11.4 years of follow-up on the 1285 random participant samples that were evaluated for sTNF-R1 and sTNF-R2 levels as part of an ancillary study.
Serum Biomarker Measurements
Blood samples were obtained in the morning, and after processing, the specimens were frozen at −70°C and shipped to the Health ABC Core Laboratory at the University of Vermont. Cytokines and cytokine-soluble receptors were measured in duplicate by an ELISA kit from R&D Systems (Minneapolis, MN). The detectable limit for TNF (HSTA50 kit), sTNF-R1 (DRT100 kit), and sTNF-R2 (DRT200 kit) was 0.18, 3, and 1 pg/mL, respectively. Blind duplicate analyses (n=150) for TNF showed interassay coefficients of variation of 15.8%.
Study Outcomes
All first overnight hospitalizations adjudicated to be related to HF were classified as incident HF. All participants were asked to report any hospitalization and were asked for information about interim events every 6 months. When an event was reported, hospital records were collected and verified by the Health ABC disease adjudication committee at each site. Adjudication criteria required, in addition to a physician diagnosis of HF, (1) medical record documentation of HF symptoms and signs; (2) supporting clinical findings, for example, chest radiography or echocardiography; and (3) medical therapy for HF, including at least a diuretic and a vasodilator or digitalis. Incident coronary heart disease was defined as hospitalization for myocardial infarction, angina pectoris, or elective coronary revascularization, either surgical or percutaneous. Date and causes of death were taken from the death certificate.
Statistical Analysis
Data are presented as mean (SD) for continuous, and percentage for categorical variables. Differences between groups were assessed using the nonparametric rank-sum test (Mann-Whitney) for continuous and Fisher exact test for categorical variables. Univariate relationship between TNF, sTNF-R1, and sTNF-R2 with HF risk was examined with Cox proportional hazards models. Because the distribution of TNF, sTNF-R1, and sTNF-R2 was lognormal, these were log-transformed. Log 2 basis was used to facilitate interpretation; the hazard ratio per log 2 increase expresses the risk associated with doubling of levels. Incident HF rates were calculated with the Kaplan-Meier method. The multivariable Cox models were controlled for the Health ABC HF risk model, which includes age, history of coronary heart disease, smoking, systolic blood pressure, creatinine, albumin, heart rate, fasting glucose, and left ventricular hypertrophy. We also controlled for ankle-arm index as a marker of subclinical vascular disease and time-varying incident coronary events. 20 The association between TNF, sTNF-R1, and sTNF-R2 with incident HF was evaluated for effect modification with sex and race using appropriate interaction terms, and effect of these markers on risk for HF with preserved versus reduced ejection fraction was assessed. The proportional hazards assumption was evaluated by examining the Schoenfeld residuals. A 2-sided P <0.05 was accepted as statistically significant. Analyses were performed with STATA 12.1 (StataCorp LP, College Station, TX).
Results
Participant Characteristics
The mean age of study participants was 74.0±2.9 years, and 51.4% were women and 41.1% were black (Table 1) . At baseline, median (interquartile range) TNF, sTNF-R1, and sTNF-R2 levels were 3.14 ( 
Incident HF
During a median follow-up of 11.4 (6.9−11.7) years, 233 (18.1%) participants developed HF and 431 died. Of the remaining 621 patients, information was not available after the 10-year follow-up visit for 30 patients; therefore, loss to follow-up accounted for 4.8% of censoring. Of those who developed HF, 171 (73.3%) had ejection fraction determined and documented at the time of HF diagnosis. The median ejection fraction was 41.5%. Overall, 47.6% had preserved ejection fraction (≥45%) and 52.3 had reduced ejection fraction (<45%).
Baseline TNF was associated with a significantly higher risk of HF (hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.23-1.89 per log 2 increase; P=0.0001), as was sTNF-R1 (HR, 2.36; 95% CI, 1.71-3.25 per log 2 increase; P<0.0001) and sTNF-R2 (HR, 1.52; 95% CI, 1.16-2.00 per log 2 increase; P=0.003). After controlling for the Health ABC HF risk score, TNF and sTNF-R1 remained associated with a higher risk (HR, 1.28; 95% CI, 1.02-1.61; P=0.037 for TNF, and HR, 1.68; 95% CI, 1.15-2.46; P=0.008 for sTNF-R1), whereas sTNF-R2 was not significant anymore (HR, 1.15; 95% CI, 0.80-1.63; P=0.45). Additional adjustment for baseline ankle-arm index and time-varying incident coronary events attenuated the association for TNF but not sTNF-R1 ( Table 2) . Addition of TNF-R1 to the Health ABC HF model did not demonstrate material improvement in net discrimination or reclassification (Table 3 ).
Subgroups
Levels of TNF, sTNF-R1, and sTNF-R2 and incident HF risk were consistent across whites versus blacks (interaction P=0.531, 0.091, and 0.795 for TNF, sTNF-R1, and sTNF-R2, respectively) and across both sexes (interaction P=0.491, 0.672, and 0.999 for TNF, sTNF-R1, and sTNF-R2, respectively). After adjusting for Health ABC HF risk model and stratified by baseline coronary heart disease, no significant differences were found between levels of sTNF-R1 and sTNF-R2 above and below the median and incident HF among several subgroups, including, age, sex, race, smoking status, presence of left ventricular hypertrophy, type 2 diabetes mellitus, and coronary heart disease (Figure) . sTNF-R1 was associated with a higher risk of incident HF in patients who developed HF with preserved ejection fraction (≥45%; HR, 1.81; 95% CI, 1.03-3.18; P=0.038) and not those with reduced ejection fraction (<45%; HR, 0.90; 95% CI, 0.56-1.44; P=0.667; interaction P=0.05; Table 4 ).
Discussion
The traditional risk markers for cardiovascular disease have limited predictive value in the elderly persons. Moreover, risk prediction for incident HF has been less studied compared with coronary diseases, especially in the elderly persons, and currently there are no targeted HF risk assessment and prevention recommendations, barring control of individual comorbidities such as hypertension. However, considering the growing elderly population and the projected worsening of HF epidemiology, 22 concentrated efforts are needed for assessment of traditional and novel risk factors for HF risk prediction, but more importantly to elucidate pathways that mediate the high risk in order to develop effective prevention interventions. In this cohort of older adults, we observed that elevated serum levels of sTNF-R1 are associated with increased risk for incident HF. sTNF-R1 had a stronger association with incident HF, compared with TNF. This association persisted in models adjusting for established HF risk factors, baseline markers of subclinical atherosclerosis, and interim coronary events. Importantly, consistent with the cytokine analysis of the vesnarinone trial, 23 these findings were consistent across sex and race. †The reference risk prediction model included the Health ABC heart failure risk model, which was then extended to additionally include sTNF-R1 as the alternative model.
Inflammation has long been associated with chronic HF and plays an important role in the pathogenesis of HF through direct effects on myocardial function. 8 Previous studies have suggested a strong association between circulating levels of inflammatory cytokines and risk of HF. [9] [10] [11] [12] [13] In the Framingham Heart Study, 9 there was a 68% increase in risk of incident HF per tertile increment in TNF (mg/dL) among participants with no previous history of myocardial infarction or HF. 9 A study from the Health ABC Study demonstrated a significant association between inflammatory markers interleukin-6, C-reactive protein, and TNF, and heightened risk of incident HF among older persons. 13 In addition, there is evidence to suggest that these inflammatory cytokines are elevated in individuals with asymptomatic left ventricular systolic and diastolic dysfunction. 24 These recent studies, in addition to results from the current study, support a more direct role for inflammation in HF development than was previously thought. 9, 10, 12, 13 We found that sTNF-R1 was associated with incident HF, whereas increased levels of sTNF-R2 were not. 25 Aside from erythrocytes, sTNF-R1 is expressed in nearly all cell types, including vascular and myocardial cells. 26 sTNF-R2 is found primarily in cells of the immune system, but also in the heart. Although the consequences of sTNF-R2 signaling are less well characterized, it is known that sTNF-R2 mediates signals that promote tissue repair and angiogenesis. 27 Whereas, proinflammatory and apoptotic pathways are mediated largely through sTNF-R1. 25 Previous research suggests that although the relationship of sTNF-R1 and sTNF-R2 signaling is complex, it seems that sTNF-R1 aggravates, whereas sTNF-R2 ameliorates, chamber remodeling and hypertrophy, largely because of disparate, opposing effects on nuclear factor-kB, inflammatory activation, and apoptosis. 28 These differential receptor functional properties could explain why the risk associated with these receptors might vary. One study found that sTNF-R1 emerged as the strongest independent predictor, regardless of follow-up duration and independent of established markers, of HF severity. 29 TNF contributes to the progression of HF through a variety of mechanisms. 30 TNF is known to exert direct effects on cardiomyocyte contractility 31, 32 and can influence left ventricular remodeling and hypertrophy. [33] [34] [35] In the failing heart, TNF induces β-adrenergic receptor uncoupling, 36 increases reactive oxygen species formation, 37 and increases inducible NO synthase synthesis, resulting in high-output NO formation, 37 all of which contribute to contractile dysfunction. Apart from its functional effects, sustained expression of TNF at high concentrations contributes to structural alterations in the failing heart, such as cardiomyocyte hypertrophy, increased cardiomyocyte apoptosis, and cardiac fibrosis. In addition to direct myocardial effects, inflammatory cytokines have been implicated in the pathogenesis of other aspects of the HF syndrome, such as pulmonary edema, skeletal muscle atrophy, and cachexia. 38, 39 Circulating cytokine receptors play an important role in these deleterious effects of the inflammatory process. In fact, previous studies conducted in smaller cohorts suggest that circulating levels of sTNF-R1 and sTNF-R2 are more strongly correlated with severity of HF, compared with TNF. 29, 40, 41 Our study further supports these findings, demonstrating the incremental value of sTNF-R1 levels in the prediction of incident HF among the elderly persons, whereas elevated levels of TNF did not add any incremental predictive value over traditional HF risk factors.
It is interesting to note that sTNF-R1 levels were associated with a higher risk for HF with preserved ejection fraction compared with reduced ejection fraction. These data should be interpreted with caution, because the ejection fraction data at the time of diagnosis of HF were not uniformly available, and therefore these results are prone to selection bias and other confounding. Nevertheless, it is interesting to note that inflammation is a more important predictor of incident HF with preserved ejection fraction in older adults, and these data complement the recent interest in the role of systemic inflammation as a common denominator explaining the relationship between comorbidity burden and risk for HF with preserved ejection fraction. These data need further validation. 42 Our study has several limitations. Diagnosis of HF was based on HF hospitalization. Therefore, the rate of incident HF in our study was likely underestimated because some participants may have developed HF while not requiring hospitalization. Furthermore, echocardiography was not performed at baseline in the Health ABC Study; therefore, participants with asymptomatic structural heart abnormalities may have been included in the analysis. However, because HF is unlikely to remain undiagnosed for several years, the observed associations cannot be ascribed merely to undetected HF at baseline.
In conclusion, we demonstrate a significant association between elevated levels of the TNF receptor, sTNF-R1, and risk of HF in older adults. These findings were consistent across sex-and race-based groups and persisted after controlling for HF risk factors. However, addition of TNF-R1 to the previously validated Health ABC HF risk model did not demonstrate material improvement in net discrimination or reclassification. The diagnostic and therapeutic meaning of these results need further study.
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